Abstract
Respiratory syncytial virus (RSV) is the most significant cause of pediatric respiratory infections. Palivizumab (Synagis®), a humanized monoclonal antibody, has been used successfully for a number of years to prevent severe RSV disease in at-risk infants. However, despite intense efforts, there is no approved vaccine or small molecule drug for RSV. As an enveloped virus, RSV must fuse its envelope with the host cell membrane, which is accomplished through the actions of the fusion (F) glycoprotein, with attachment help from the G glycoprotein. Because of their integral role in initiation of infection and their accessibility outside the lipid bilayer, these proteins have been popular targets in the discovery and development of antiviral compounds and vaccines against RSV. This review examines advances in the development of antiviral compounds and vaccine candidates.
Citations
Jan 28, 2014·Archives of Disease in Childhood·Joanna MurrayMike Sharland
Jun 18, 2014·ILAR Journal·Mark R Ackermann
Dec 4, 2013·Archives of Virology·Qiuling XiaEnmei Liu
Nov 15, 2013·Influenza and Other Respiratory Viruses·Frederick G Hayden
Nov 21, 2013·Journal of Microscopy·P M TiwariS R Singh
Jan 3, 2014·Advances in Virology·Swapnil Subhash BawageShree Ram Singh
Oct 4, 2016·Vaccine·Asuncion MejiasOctavio Ramilo
Mar 9, 2017·Human Vaccines & Immunotherapeutics·Mohamed A FarragFahad N Almajhdi
Mar 1, 2017·The Journal of Microbiology·Megan E Schmidt, Steven M Varga
Apr 24, 2018·The Journal of Infectious Diseases·Marita StevensRené Verloes
Mar 11, 2016·F1000Research·Wade Blair, Christopher Cox
Feb 7, 2015·Journal of Biomolecular Screening·Helen PlantKirsty Rich
May 11, 2018·Journal of Virology·Stephanie N HicksMark E Peeples
Feb 7, 2019·Nature Reviews. Microbiology·Michael B Battles, Jason S McLellan
Nov 10, 2018·Journal of Medicinal Chemistry·G Stuart CockerillNeil Mathews